How effective is it for pharma pricing & forecasting? Some evidence-based answers

In this on-demand webinar, discover the differences between FTIR, NIR and Raman spectroscopy, learn how spectroscopy is applied in quality control labs and hear how implementation of these techniques increased efficiency and minimised costs.

There are approximately 7,000 distinct rare diseases affecting 350 million people worldwide, approximately 80 percent of which are caused by faulty genes. Scientific advances such as the CRISPR/Cas9 genome-engineering system have simplified the pharmaceutical and biotech industry’s ability to develop gene therapies, especially for single gene mutation disorders. The US Food and Drug Administration (FDA) has more than 700 active Investigational New Drug Applications (INDs) for gene and cell therapies and in 2017, the FDA approved two cell-based gene therapies and it is anticipated that gene therapy will become a mainstay treatment for many rare diseases.

Find out which market-moving events and catalysts to watch for during the upcoming Q1 Outlook Webinar - Key catalysts and their impact on pharma markets. During this webinar recording, industry analysts from Informa Pharma Intelligence present their data-based views on what’s in store for key drugs in early 2019. Discussion include important upcoming events related to these key drugs, their likelihood of phase/PDUFA review success and likelihood of approval, and an examination of the market significance of the drugs themselves.

Advanced therapy clinical trials are growing, with a record number of therapies being approved in 2021. This increase in approvals has led many to predict that the commercialization of advanced therapies is not far away .